Get the Stockscreener App
20.14
2.23%
0.44
After Hours:
20.14
Lyell Immunopharma Inc stock is traded at $20.14, with a volume of 79,804.
It is up +2.23% in the last 24 hours and down -14.22% over the past month.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
See More
Previous Close:
$19.70
Open:
$19.55
24h Volume:
79,804
Relative Volume:
0.70
Market Cap:
$469.41M
Revenue:
$36,000
Net Income/Loss:
$-274.45M
P/E Ratio:
-1.7053
EPS:
-11.8105
Net Cash Flow:
$-150.80M
1W Performance:
+0.40%
1M Performance:
-14.22%
6M Performance:
+58.33%
1Y Performance:
+91.74%
1-Day Range:
$19.55
$21.20
1-Week Range:
$17.34
$21.48
52-Week Range:
$7.65
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
20.14 | 459.15M | 36,000 | -274.45M | -150.80M | -11.81 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Dec-09-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
LYEL Technical Analysis & Stock Price Forecast - Intellectia AI
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL) - Seeking Alpha
Is Lyell Immunopharma Inc impacted by rising rates2026 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Lyell Immunopharma (LYEL) grants CFO 140,000 stock options - Stock Titan
Lyell Immunopharma (LYEL) CFO Shah identified as insider in Form 3 - Stock Titan
Lyell Immunopharma, Inc. $LYEL Shares Acquired by Foresite Capital Management V LLC - MarketBeat
Citizens reiterates Lyell Immunopharma stock rating on trial progress By Investing.com - Investing.com Canada
Lyell Immunopharma closes $50M equity tranche, names new CFO By Investing.com - Investing.com Nigeria
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update - MarketBeat
Lyell Immunopharma: Q4 Earnings Snapshot - theheraldreview.com
Lyell Immunopharma 2025 Annual Report: Advancing Next-Generation CAR T-Cell Therapies for Cancer Treatment - Minichart
Lyell Immunopharma 2025 Financial Results: Annual Loss of $274.4MNews and Statistics - IndexBox
Lyell Immunopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lyell Immunopharma (NASDAQ:LYEL) Releases Earnings Results, Misses Expectations By $5.53 EPS - MarketBeat
Lyell Immunopharma: Fourth Quarter Financial Results Overview - Bitget
Lyell Immunopharma misses Q4 revenue estimates - TradingView
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results - The Manila Times
LYEL: Pivotal CAR T-cell trials show strong efficacy, with key data updates and solid funding ahead - TradingView
ARCH Venture funds add Lyell (LYEL) stake with 488,090-share buy - Stock Titan
ARCH Venture Fund XIII boosts Lyell (LYEL) stake with 488K-share purchase - Stock Titan
Lyell Immunopharma Appoints Smital Shah as Chief Financial and Business Officer Effective March 2026 - Minichart
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap UpShould You Buy? - MarketBeat
Lyell Immunopharma, Inc. announced that it has received $99.999968 million in funding - marketscreener.com
Citizens Initiates Coverage on LYEL with Market Outperform Ratin - GuruFocus
Lyell Immunopharma (NASDAQ:LYEL) Now Covered by Citizens Jmp - MarketBeat
Lyell names Smital Shah as Chief Financial and Business Officer - TradingView
Lyell Immunopharma (NASDAQ: LYEL) hires Smital Shah as finance chief - Stock Titan
Lyell Immunopharma, Inc. Appoints Smital Shah as Chief Business Officer and Principal Financial Officer, Effective March 9, 2026 - marketscreener.com
Lyell Immunopharma Announces Closing of Additional $50 - GlobeNewswire
Citizens initiates Lyell Immunopharma stock at outperform, $34 target - Investing.com South Africa
Citizens initiates Lyell Immunopharma stock at outperform, $34 target By Investing.com - Investing.com Australia
HC Wainwright & Co. Maintains Lyell Immunopharma (LYEL) Neutral Recommendation - MSN
Take Profit: Will Lyell Immunopharma Inc benefit from rate cutsTrade Volume Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
Fund Flows: Is Lyell Immunopharma Inc impacted by rising ratesIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Breakouts Watch: Is Lyell Immunopharma Inc stock trending bullishJuly 2025 Weekly Recap & Long-Term Capital Growth Ideas - baoquankhu1.vn
Lyell Immunopharma Inc expected to post a loss of $2.37 a shareEarnings Preview - TradingView
Lyell Immunopharma (LYEL) to Release Earnings on Tuesday - MarketBeat
Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know - TipRanks
LYEL.O Technical Analysis & Stock Price Forecast - Intellectia AI
LYEL Technical Analysis & ETF Price Forecast - Intellectia AI
Lyell Immunopharma Announces Participation in March Investor Conferences - GlobeNewswire
Cancer therapy developer Lyell to join three investor conferences in March - Stock Titan
What is the long term forecast for Lyell Immunopharma Inc. stockEarnings Recap Report & Risk Managed Investment Strategies - mfd.ru
How Lyell Immunopharma Inc. stock reacts to global recession fearsPortfolio Risk Report & Weekly Return Optimization Plans - mfd.ru
What’s the MACD signal for Lyell Immunopharma Inc.Portfolio Value Summary & Free Verified High Yield Trade Plans - mfd.ru
Is Lyell Immunopharma Inc. stock gaining market shareWeekly Trend Recap & Stock Market Timing Techniques - mfd.ru
Can Lyell Immunopharma Inc. stock beat market expectations this quarterJuly 2025 Movers & Reliable Intraday Trade Alerts - mfd.ru
Will Lyell Immunopharma Inc. stock deliver shareholder valueMarket Trend Review & Fast Gaining Stock Strategy Reports - mfd.ru
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap DownHere's Why - MarketBeat
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Up 28.0% in January - MarketBeat
Can Lyell Immunopharma Inc. maintain sales growthJuly 2025 Outlook & Fast Moving Stock Trade Plans - mfd.ru
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):